Amended Report of Foreign Issuer (6-k/a)
30 Junio 2020 - 5:25AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K/A
Amendment No. 1
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of
1934
For the month of June 2020
Commission File Number: 001-37643
KITOV PHARMA LTD.
(Translation of registrant’s name
into English)
One Azrieli Center, Round Tower, Tel
Aviv 6701101, Israel
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will
file annual reports under cover Form 20-F or Form 40-F.
Form
20-F ☒
Form 40-F ☐
Indicate
by check mark if the Registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate
by check mark if the Registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
This Amendment No. 1 to Form 6-K which was furnished by Kitov
Pharma Ltd. (the “Company” or the “Registrant”) to the Commission on June 25, 2020, amends the initial
submission of the Form 6-K to replace Form of Placement Agent Warrant included as Exhibit 4.2 in the initial submission to reflect
the correct exercise price of $1.125 per ADS, instead of $0.90 as stated in the original exhibit.
Attached hereto and incorporated by reference herein are the
following exhibits:
This Form 6-K/A shall not constitute an
offer to sell or the solicitation of an offer to buy, nor shall there be any sale of ADSs or warrants in any jurisdiction in which
such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such
jurisdiction.
This Form 6-K/A,
including all exhibits attached hereto, is hereby incorporated by reference into each of
the Registrant’s Registration Statements on Form F-3 filed with the Securities and Exchange Commission on December 12, 2016
(Registration file numbers 333-207117 and 333-211477), the Registrant’s Registration Statement on Form S-8 filed with the
Securities and Exchange Commission on May 20, 2016 (Registration file number 333-211478), the Registrant’s Registration Statement
on Form S-8 filed with the Securities and Exchange Commission on June 6, 2017 (Registration file number 333-218538), the Registrant’s
Registration Statement on Form F-3, as amended, originally filed with the Securities and Exchange Commission on July 16, 2018 (Registration
file number 333-226195), the Registrant’s Registration Statement on Form S-8 filed with the Securities and Exchange Commission
on March 28, 2019 (Registration file number 333-230584), the Registrant’s Registration Statement on Form F-3 filed with the
Securities and Exchange Commission on September 16, 2019 (Registration file number 333-233795), the Registrant’s Registration
Statement on Form F-3 filed with the Securities and Exchange Commission on December 2, 2019 (Registration file number 333-235327),
the Registrant’s Registration Statement on Form F-3 filed with the Securities and Exchange Commission on May 13, 2020 (Registration
file number 333-238229), and the Registrant’s Registration Statement on Form S-8 filed with the Securities and Exchange
Commission on May 28, 2020 (Registration file number 333-238481), to be a part thereof from the date on which this report
is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly
authorized.
June 29, 2020
|
KITOV PHARMA LTD.
|
|
|
|
|
By:
|
/s/ Isaac Israel
|
|
|
Isaac Israel
|
|
|
Chief Executive Officer
|
2
Kitov Pharma (NASDAQ:KTOV)
Gráfica de Acción Histórica
De Ago 2024 a Sep 2024
Kitov Pharma (NASDAQ:KTOV)
Gráfica de Acción Histórica
De Sep 2023 a Sep 2024